These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27023706)

  • 1. Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.
    Evin G
    BioDrugs; 2016 Jun; 30(3):173-94. PubMed ID: 27023706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE inhibitors as potential therapeutics for Alzheimer's disease.
    Evin G; Kenche VB
    Recent Pat CNS Drug Discov; 2007 Nov; 2(3):188-99. PubMed ID: 18221231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
    Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
    Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease.
    Ghosh AK; Tang J
    ChemMedChem; 2015 Sep; 10(9):1463-6. PubMed ID: 26140607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE-1 Inhibitors Targeting Alzheimer's Disease.
    Monteiro KLC; Dos Santos Alcântara MG; Freire NML; Brandão EM; do Nascimento VL; Dos Santos Viana LM; de Aquino TM; da Silva-Júnior EF
    Curr Alzheimer Res; 2023; 20(3):131-148. PubMed ID: 37309767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
    Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
    Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 15. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
    Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
    CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition and modulation of gamma-secretase for Alzheimer's disease.
    Wolfe MS
    Neurotherapeutics; 2008 Jul; 5(3):391-8. PubMed ID: 18625450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
    Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
    Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Secretase Targeting for Alzheimer's Disease Therapy.
    Miranda A; Montiel E; Ulrich H; Paz C
    J Alzheimers Dis; 2021; 81(1):1-17. PubMed ID: 33749645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Moussa CE
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.